CEO Mark Bertolini Sells Nearly $83 Million in Shares as Oscar Health Surges Past 52‑Week High

Insider Selling Surges at Oscar Health Amid Strong Market Momentum

The latest Form 4 filed by CEO Mark Bertolini on June 25, 2026 reports the sale of 597,942 Class A common shares, plus an additional 17,200, 441,373 and 149,795 shares over the next two days. The transactions were executed under a Rule 10b5‑1 plan to cover tax withholdings on newly vested performance and time‑based restricted stock units. The average sale price of roughly $28.8 – $29.8 per share represents a modest discount to the close of $29.79, yet the sheer volume—nearly 2.8 million shares—amounts to a $83 million out‑flow and a 3.2 % drop in the company’s share count. The sale is well‑planned and thus unlikely to signal a lack of confidence; rather, it reflects the tax‑planning mechanics that many CEOs employ once performance awards vest.

What This Means for Investors

Oscar Health’s market has been in a strong up‑trend: a 3.2 % weekly gain, a 31.9 % monthly run‑up, and a 44 % year‑to‑date rally. The insider selling comes at a time when the stock is near its 52‑week high of $30.38, and the company’s price‑earnings ratio sits at –$47.85, indicating a heavily discounted valuation that many investors view as a buying opportunity. The Rule 10b5‑1 nature of the trades mitigates the “insider sell” negative bias that often accompanies spontaneous sales. In fact, the accompanying social‑media sentiment (+57) and buzz (360 %) suggest that the market is largely neutral to positive about the moves, perhaps interpreting them as routine tax compliance rather than a signal of looming weakness. For long‑term holders, the selling simply reduces the insider stake from about 10.2 % to roughly 9.6 %, leaving the CEO’s remaining ownership still substantial enough to align his interests with the broader shareholder base.

Bertolini’s Trading Profile

Mark Bertolini’s insider history is characterized by a mix of large, rule‑based sales and occasional opportunistic purchases. In early April he sold and bought a total of 2 million shares at $11.92, a price far below the current level, indicating a disciplined approach to liquidity management. Over the past year, he has executed several performance‑unit related sales, most recently on April 3, 2026 (5.73 million units) and April 6, 2026 (1 million shares). These actions reveal a pattern of using vesting schedules to trigger systematic, pre‑planned sales—common among CEOs of high‑growth tech and health‑tech firms. His net position has fluctuated but remains comfortably above 9 % of the outstanding shares, suggesting confidence in the company’s trajectory.

Broader Insider Activity Context

While Bertolini’s trades are the headline, other top executives—Mario Schlosser, David Plouffe, and Richard Scott—have also been active. Schlosser’s recent activity includes a mix of large purchases (up to 1 million shares) and sales that net to a modest increase in his holdings. The overall insider sentiment appears stable, with the CEO’s consistent use of 10b5‑1 plans indicating a focus on compliance rather than opportunism. For investors, the key takeaway is that Oscar Health’s leadership is actively managing tax liabilities without undermining the long‑term ownership structure, while the stock’s recent price momentum and low valuation continue to provide a compelling case for equity participation.